Download Supplementary Movie File from Toward Molecular Imaging–Driven Drug Development in Oncology

Format: .mp4; Size: 59 MB.Description of Movie Many rapidly dividing tumor cells express or overexpress surface receptor molecules that can be targeted with antibodies. Tracers (for example, the radionuclide zirconium-89) can be attached to these antibodies and administered to patients. Once the antibody reaches the surface receptor on the tumor cell, it is internalized and digested in an endosome, releasing the tracer. Accumulation of the tracer in the tumor cells can then be visualized.NOTE: There is no audio component associated with this video file.</p

Supplementary Figure 2 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

Dasatinib in combination with cisplatin in resistant TC cells</p

Supplementary Figure 4 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

mTORC1/2 downstream pathway evaluation in Tera cells</p

Supplementary Figure 1 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

Cisplatin sensitivity in TC cells and RTK validation on western blot</p

Supplementary Figure 3 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

mTOR knock down in combination with cisplatin in resistant TC cells</p

Supplementary Figure 7 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

PDGFRbeta protein expression in TC cell lines</p

Supplementary Figure 6 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

mTORC1/2 inhibition in combination with cisplatin in TC PDX models</p

Supplementary Figure 5 from Dual mTORC1/2 Inhibition Sensitizes Testicular Cancer Models to Cisplatin Treatment

Autophagy induction and the effect on apoptosis in cisplatin resistant TC cells</p